Interestingly, these findings were not corroborated by the PFS subgroup data from KEYNOTE-189 which displayed a correlation between benefit and PD-L1 expression level, or by the results of KEYNOTE-407 with pembrolizumab plus chemotherapy in SQ NSCLC which also reported a dose-relationship between PD-L1 expression level and survival benefit (for both OS and PFS). The gene discussed is CD274; the disease is non-small cell lung carcinoma.